Subcutaneous Injectable Drugs Hypersensitivity and Desensitization Insulin and Monoclonal Antibodies

BAVBEK S., Lee M. J.

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, cilt.37, sa.4, ss.761-772, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Sayı: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1016/j.iac.2017.06.001
  • Dergi Adı: IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.761-772
  • Anahtar Kelimeler: Adalimumab, Etanercept, Omalizumab, Insulin, Injection site reactions, Systemic hypersensitivity reactions, MoAbs, TNF-alpha inhibitors, INJECTION-SITE REACTIONS, OMALIZUMAB-ASSOCIATED ANAPHYLAXIS, RHEUMATOID-ARTHRITIS, IMMUNOLOGY/AMERICAN-COLLEGE, ADALIMUMAB DESENSITIZATION, AMERICAN-ACADEMY, DIABETIC-PATIENT, SKIN-TESTS, ETANERCEPT, ALLERGY
  • Ankara Üniversitesi Adresli: Evet

Özet

Injectable drugs, including monoclonal antibodies, are becoming crucial components in the management of chronic diseases. The most common side effects are local reactions at the site of administration. With the increased and prolonged use of these medications, we are seeing increased reports of hypersensitivity reactions. The aim of this article is to discuss the signs and symptoms of these reactions as well as management, which may involve desensitization for 3 commonly encountered injectable drugs: tumor necrosis factor-alpha inhibitors (etanercept and adalimumab), insulin, and omalizumab.